Revolution Medicines is trading 10.63% lower at $178.47 as biotech stocks and major indexes fall in a sharp risk-off session.
- Executives said five weeks of RASONQUE sales were too early to establish a normalized launch trajectory.
- Some early demand came from finite patient groups.
- Initial revenue of $197.6 million beat expectations.